These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 558637)

  • 41. Effect of dazoxiben on platelet-vessel wall interaction.
    Davies JA; Menys VC
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):45S-46S. PubMed ID: 6681703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of platelet thromboxane synthetase by 1-(3-benzyloxy-1[E]octenyl)imidazole.
    Sincholle D; Coquelet C; Bonne C
    Arzneimittelforschung; 1986; 36(1):117-9. PubMed ID: 3082339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives.
    Iizuka K; Akahane K; Momose D; Nakazawa M; Tanouchi T; Kawamura M; Ohyama I; Kajiwara I; Iguchi Y; Okada T; Taniguchi K; Miyamoto T; Hayashi M
    J Med Chem; 1981 Oct; 24(10):1139-48. PubMed ID: 7199088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of novel arachidonic acid metabolites formed by prostaglandin H synthase.
    Hecker M; Ullrich V; Fischer C; Meese CO
    Eur J Biochem; 1987 Nov; 169(1):113-23. PubMed ID: 3119336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes.
    Needleman P; Kulkarni PS; Raz A
    Science; 1977 Jan; 195(4276):409-12. PubMed ID: 831285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
    Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
    J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Solubilization and resolution of thromboxane synthesizing system from microsomes of bovine blood platelets.
    Yoshimoto T; Yamamoto S; Okuma M; Hayaishi O
    J Biol Chem; 1977 Aug; 252(16):5871-4. PubMed ID: 885887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biosynthesis of thromboxanes in human platelets. I. Characterization and assay of thromboxane synthetase.
    Sun FF
    Biochem Biophys Res Commun; 1977 Feb; 74(4):1432-40. PubMed ID: 843369
    [No Abstract]   [Full Text] [Related]  

  • 50. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kinetic studies on the conversion of prostaglandin endoperoxide PGH2 by thromboxane synthase.
    Anderson MW; Crutchley DJ; Tainer BE; Eling TE
    Prostaglandins; 1978 Oct; 16(4):563-70. PubMed ID: 725086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
    Gorman RR; Fitzpatrick FA; Miller OV
    Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
    [No Abstract]   [Full Text] [Related]  

  • 53. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT; Basevich VV; Varfolomeev SD
    Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
    Moncada S; Gryglewski R; Bunting S; Vane JR
    Nature; 1976 Oct; 263(5579):663-5. PubMed ID: 802670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A possible role of thromboxane A2 (TXA2) and prostacyclin (PGI2) in circulation.
    Gryglewski RJ; Dembínska-Kieć A; Korbut R
    Acta Biol Med Ger; 1978; 37(5-6):715-23. PubMed ID: 369254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thromboxane synthetase inhibitors differentially antagonize thromboxane receptors in vascular smooth muscle.
    Smith EF; Lefer AM; Smith JB; Nicolaou KC
    Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(2):130-4. PubMed ID: 6276789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion.
    Charo IF; Feinman RD; Detwiler TC; Smith JB; Ingerman CM; Silver MJ
    Nature; 1977 Sep; 269(5623):66-9. PubMed ID: 895887
    [No Abstract]   [Full Text] [Related]  

  • 59. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides.
    Di Minno G; Bertelé V; Cerletti C; de Gaetano G; Silver MJ
    Thromb Res; 1982 Feb; 25(4):299-306. PubMed ID: 6803385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.